Cephalosporins, Carbapenems, Monobactams and Other Cell-Wall Active Antibiotics

3rd Year MBBS • Infection and Inflammation

A rapid integration of antibacterial spectrum, pharmacokinetics, clinical use, resistance and important toxicities.

1. THE TOPIC IN ONE CONNECTED FLOW

These antibiotics share one central therapeutic goal: weakening bacterial cell-wall formation. Their clinical roles differ because each drug group has a different spectrum, target, route of administration, tissue penetration and toxicity profile. The key is to connect the organism being treated with the drug that can reach it, inhibit its cell wall and do so safely.

Drug Selection

Identify required antibacterial spectrum

→

Cell-Wall Target

PBP inhibition or other peptidoglycan blockade

→

Functional Effect

Weak or incomplete bacterial cell wall

→

Bacterial Killing

Loss of cell-wall integrity during growth

→

Clinical Success Depends On

Spectrum + site penetration + adequate exposure

→

Limits to Therapy

Resistance, allergy and characteristic toxicities

Cephalosporins
Generation determines spectrum → PK determines site of use → beta-lactamases may cause resistance.

Carbapenems
Very broad coverage → useful in severe, complicated or resistant infections.

Aztreonam
Aerobic gram-negative activity → useful when focused gram-negative coverage is required.

Vancomycin
D-Ala-D-Ala binding → gram-positive activity → major role in MRSA.

2. KEY CLINICAL CONNECTIONS

Cephalosporin Selection

Suspected organism → choose appropriate generation → confirm required site penetration → maintain adequate time above MIC.

Example: CNS infection → ceftriaxone or cefotaxime because useful CSF concentrations can be achieved when meninges are inflamed.

Broad vs Focused Coverage

Severe polymicrobial infection → broad aerobic + anaerobic coverage → carbapenem may be appropriate.

Aerobic gram-negative infection only → focused spectrum → aztreonam may avoid unnecessary gram-positive and anaerobic coverage.

MRSA and Vancomycin

Altered PBP2a → many beta-lactams lose activity → vancomycin bypasses the PBP target by binding D-Ala-D-Ala.

Rapid IV infusion → histamine release → flushing, erythema and hypotension of Red Man/Red Neck syndrome.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ Cephalosporin generation → spectrum: earlier agents emphasize susceptible gram-positive cocci, while later generations generally expand gram-negative coverage.

Cephalosporin PK → clinical use: most are renally eliminated, while ceftriaxone has important biliary elimination; CSF penetration explains the meningitis role of ceftriaxone and cefotaxime.

⭐ Time-dependent killing → dosing logic: cephalosporin effectiveness improves when free drug concentrations remain above the MIC for an adequate period.

Beta-lactamase production → hydrolysis of beta-lactam ring → loss of effective PBP binding → cephalosporin resistance.

Carbapenem spectrum → severe infection role: broad gram-positive, gram-negative and anaerobic activity makes these drugs useful in selected serious and complicated infections.

Aztreonam spectrum → focused use: aerobic gram-negative coverage, including susceptible Pseudomonas, with little useful gram-positive or anaerobic activity.

⭐ Vancomycin target → MRSA benefit: D-Ala-D-Ala binding blocks peptidoglycan construction without relying on the altered PBP2a target.

Characteristic restricted uses: fosfomycin → susceptible uncomplicated UTI; bacitracin → topical infection; cycloserine → second-line treatment of resistant tuberculosis.

AIM Exam Trap:
Do not confuse the special roles: ceftazidime/cefepime → Pseudomonas, ceftaroline → MRSA, and ertapenem → no reliable Pseudomonas coverage.